Lipella Pharmaceuticals Inc. Common Stock (NASDAQ:LIPO) — Market Cap & Net Worth
Market Cap & Net Worth: Lipella Pharmaceuticals Inc. Common Stock (LIPO)
Lipella Pharmaceuticals Inc. Common Stock (NASDAQ:LIPO) has a market capitalization of $111.36K ($111.36K) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30948 globally and #5965 in its home market, demonstrating a -59.83% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lipella Pharmaceuticals Inc. Common Stock's stock price $0.02 by its total outstanding shares 4620837 (4.62 Million). Analyse LIPO cash generation efficiency to see how efficiently the company converts income to cash.
Lipella Pharmaceuticals Inc. Common Stock Market Cap History: 2022 to 2026
Lipella Pharmaceuticals Inc. Common Stock's market capitalization history from 2022 to 2026. Data shows change from $115.71 Million to $111.36K (-88.76% CAGR).
Index Memberships
Lipella Pharmaceuticals Inc. Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #925 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2912 of 3165 |
Weight: Lipella Pharmaceuticals Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Lipella Pharmaceuticals Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lipella Pharmaceuticals Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
27.22x
Lipella Pharmaceuticals Inc. Common Stock's market cap is 27.22 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $115.71 Million | $184.16K | -$2.60 Million | 628.30x | N/A |
| 2023 | $37.71 Million | $449.62K | -$4.62 Million | 83.86x | N/A |
| 2024 | $14.60 Million | $536.36K | -$5.02 Million | 27.22x | N/A |
Competitor Companies of LIPO by Market Capitalization
Companies near Lipella Pharmaceuticals Inc. Common Stock in the global market cap rankings as of May 2, 2026.
Key companies related to Lipella Pharmaceuticals Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Lipella Pharmaceuticals Inc. Common Stock Historical Marketcap From 2022 to 2026
Between 2022 and today, Lipella Pharmaceuticals Inc. Common Stock's market cap moved from $115.71 Million to $ 111.36K, with a yearly change of -88.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $111.36K | -85.91% |
| 2025 | $790.16K | -94.59% |
| 2024 | $14.60 Million | -61.27% |
| 2023 | $37.71 Million | -67.41% |
| 2022 | $115.71 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Lipella Pharmaceuticals Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $111.36K USD |
| MoneyControl | $111.36K USD |
| MarketWatch | $111.36K USD |
| marketcap.company | $111.36K USD |
| Reuters | $111.36K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lipella Pharmaceuticals Inc. Common Stock
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen plan… Read more